Enyedy Mark J — SEC Form 4 filings
SEC reporting owner CIK 1586965. 8 Form 4 filings on record with FilingPulse; latest filed 2026-06-04.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2024-02-05 to 2026-06-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 20,107 shares, $588,733 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: sale of 20,107 shares @ $29.28 ($588,733) in ImmunoGen, Inc., filed 2024-02-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ImmunoGen, Inc. (IMGN) | CHIEF EXECUTIVE OFFICER, Director | 3 | — | 1 leg · 20,107 sh · $588,733 | 11 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | Director | 3 | — | — | 3 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | Director | 2 | — | — | 3 |
Form 4 filings — Enyedy Mark J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-04 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 7,490 @ $0 | EDGAR |
| 2026-05-11 | 4 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | Grant/award (A): 1,438 @ $177.62 | EDGAR |
| 2025-06-04 | 4 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | Grant/award (A): 946 @ $135.04 · Grant/award (A): 2,082 (derivative) @ $135.04 | EDGAR |
| 2025-05-22 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 6,650 @ $0 | EDGAR |
| 2024-05-23 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 4,720 @ $0 | EDGAR |
| 2024-02-12 | 4 | ImmunoGen, Inc. (IMGN) | Disposition to issuer (D): 584,397 · Disposition to issuer (D): 102,466 (derivative) · Disposition to issuer (D): 140,357 (derivative) · Disposition to issuer (D): 196,875 (derivative) · Disposition to issuer (D): 925,000 (derivative) · Disposition to issuer (D): 1,100,000 (derivative) · +2 more | EDGAR |
| 2024-02-06 | 4 | ImmunoGen, Inc. (IMGN) | Option exercise (M): 51,234 @ $0 · Sale (S): 20,107 @ $29.28 · Option exercise (M): 51,234 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | ImmunoGen, Inc. (IMGN) | Grant/award (A): 140,357 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1586965 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →